Ani Pharmaceuticals (ANIP) Change in Accured Expenses (2010 - 2018)

Ani Pharmaceuticals has disclosed Change in Accured Expenses across 9 years of filings, most recently posting $1.0 million for Q3 2018.

• Change in Accured Expenses for Q3 2018 came in at $1.0 million, down 43.14% year-over-year; the trailing twelve-month figure through Sep 2018 was $174000.0 (up 74.0% YoY), and the FY2017 annual result was $644000.0, down 31.49% from the prior year.
• Change in Accured Expenses came in at $1.0 million for Q3 2018 at Ani Pharmaceuticals, up from -$749000.0 in the prior quarter.
• In the past five years, Change in Accured Expenses ranged from a high of $1.8 million in Q3 2017 to a low of -$1.9 million in Q4 2015.
• The 5-year median for Change in Accured Expenses is $143000.0 (2014), against an average of $171473.7.
• Across the five-year window, Change in Accured Expenses slumped 523.08% in 2015 and surged 45125.0% in 2017, its largest moves.
• Ani Pharmaceuticals' Change in Accured Expenses stood at -$630000.0 in 2014, then plunged by 198.57% to -$1.9 million in 2015, then grew by 8.88% to -$1.7 million in 2016, then surged by 31.74% to -$1.2 million in 2017, then surged by 187.52% to $1.0 million in 2018.
• The last three Change in Accured Expenses figures came in at $1.0 million (Q3 2018), -$749000.0 (Q2 2018), and $1.1 million (Q1 2018), per Business Quant data.